Conclusions
Case report of a patient who has remained on enzyme replacement therapy for more than 6 years, with adequate adherence to the pharmacological treatment and no adverse reactions. GAG levels in the urine have remained stable. The course of the disease has been slow in terms of cardiac and pulmonary involvement, while observed improvements in motor skills and pain control have enabled the patient to continue in school. These findings support the long-term benefits of slowing the progression of the disease with galsulfase-based ERT as an option to modify the natural history of the disease and the quality of life in patients with MPS VI.